South Africa Expands Lenacapavir HIV Prevention Rollout

Demand for the twice-yearly HIV-prevention injection is growing, raising concerns about limited supply.

Updated on Nov. 22, 2026 in Health

South Africa Expands Lenacapavir HIV Prevention Rollout

Live Poll

Would you get an HIV-prevention injection if it were available near you?

South Africa's Health Department reported growing demand for lenacapavir, a twice-yearly injection that prevents HIV, as the national rollout officially launched on 5 June 2026. Access is currently restricted to 360 public health facilities across 24 districts in six provinces.

Why it matters

Supplies of lenacapavir are limited and depend on Global Fund allocations, so rising demand raises questions about whether stock can meet need. Affordability concerns also remain until a generic version becomes available.

Access is restricted to 360 public health facilities across 24 districts in six provinces, with all Phase 1 facilities having trained providers. The source does not state how many clients have been reached or how long current supply will last.

The players

South African Department of Health

The national health ministry responsible for public health policy and the rollout of HIV-prevention services across the country's provinces.

Gilead Sciences

The American biopharmaceutical company that is the main manufacturer of lenacapavir, an HIV-prevention drug approved for twice-yearly injection.

The details

Clients undergo screening, monitoring and counselling at participating facilities before and during injections, and must test HIV-negative before starting and before each continuation injection. Stock availability is tracked through the SyNCH and departmental pharmaceutical monitoring systems, and Gilead is the main manufacturer.

Timeline

  1. 5 June 2026: National rollout of lenacapavir officially launched.

  2. April 2026: South Africa received its first batch of lenacapavir.

  3. 20 November 2026: Clients are due for their continuation injections.

Health Landscape

South Africa's lenacapavir supply depends on Global Fund allocations, tying the rollout to donor-funded HIV-prevention programmes rather than domestic procurement. Limited supply and affordability concerns persist until a generic version of the drug is introduced.

Clients must test HIV-negative before starting lenacapavir and before each continuation injection, which is a twice-yearly commitment. Access is limited to designated public health facilities in six provinces for now, so people outside those areas cannot yet begin the injection there.

The takeaway

Anyone eligible in the rollout areas should check whether their nearest public health facility is among the 360 participating sites. Planning for the twice-yearly continuation injections, including the HIV test required before each one, can help keep the schedule on track.

What happens next

Continuation injections for clients are due from 20 November 2026, when access and stock availability will be tested for the first recipients.

Further reading

Explore more health general coverage for context on the country's HIV-prevention efforts.

Source note: This article includes information reported by IOL.

Live Poll

Would you get an HIV-prevention injection if it were available near you?